Our top pick for
MediciNova Inc is a biotechnology business based in the US. MediciNova shares (MNOV) are listed on the NASDAQ and all prices are listed in US Dollars. MediciNova employs 9 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$3.56|
|52-week range||$3.33 - $7.45|
|50-day moving average||$3.83|
|200-day moving average||$3.98|
|Wall St. target price||$16.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.24|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||-5.57%|
|1 month (2021-09-24)||-8.72%|
|3 months (2021-07-26)||-0.84%|
|6 months (2021-04-26)||-23.77%|
|1 year (2020-10-26)||-35.27%|
|2 years (2019-10-25)||-53.40%|
|3 years (2018-10-26)||9.06|
|5 years (2016-10-26)||7.07|
|Revenue TTM||$4 million|
|Gross profit TTM||$0|
|Return on assets TTM||-8.3%|
|Return on equity TTM||-13.92%|
|Market capitalisation||$179.2 million|
TTM: trailing 12 months
There are currently 1.7 million MediciNova shares held short by investors – that's known as MediciNova's "short interest". This figure is 9.1% down from 1.9 million last month.
There are a few different ways that this level of interest in shorting MediciNova shares can be evaluated.
MediciNova's "short interest ratio" (SIR) is the quantity of MediciNova shares currently shorted divided by the average quantity of MediciNova shares traded daily (recently around 107823.23547783). MediciNova's SIR currently stands at 16.01. In other words for every 100,000 MediciNova shares traded daily on the market, roughly 16010 shares are currently held short.
However MediciNova's short interest can also be evaluated against the total number of MediciNova shares, or, against the total number of tradable MediciNova shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MediciNova's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 MediciNova shares in existence, roughly 40 shares are currently held short) or 0.042% of the tradable shares (for every 100,000 tradable MediciNova shares, roughly 42 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against MediciNova.
Find out more about how you can short MediciNova stock.
We're not expecting MediciNova to pay a dividend over the next 12 months.
MediciNova's shares were split on a 1:10 basis on 30 October 2006. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MediciNova shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for MediciNova shares which in turn could have impacted MediciNova's share price.
Over the last 12 months, MediciNova's shares have ranged in value from as little as $3.33 up to $7.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MediciNova's is 1.4386. This would suggest that MediciNova's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
MediciNova, Inc. , a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.